Literature DB >> 12182379

Instituting a routine varicella vaccination program in Canada: an economic evaluation.

Denis Getsios1, J Jaime Caro, Graciela Caro, Phillipe De Wals, Barbara J Law, Yves Robert, Jean-Marie R Lance.   

Abstract

BACKGROUND: After licensing of a varicella vaccine in Canada in 1998, Health Canada commissioned a study to evaluate options for a vaccination program. The evaluation of a program of vaccination of 12-month-old children, with and without a catch-up program for susceptible 12-year-olds, is presented here.
METHODS: An economic model was developed simulating the expected experience, with and without vaccination, of cohorts of children susceptible to varicella. The cohorts were simulated for 70 years, and infection and complication rates were calculated along with the attendant costs, with an assumed vaccine cost of $60.
RESULTS: With an 85% coverage rate vaccination is expected to reduce the number of chickenpox cases by approximately two-thirds and varicella-related complications by up to 75%. The overall costs of varicella are expected to drop by >$4 million (1998 Canadian dollars) per 100,000 eligible vaccinees, but costs to the health care system are expected to increase by >$2 million. From the health care system perspective, vaccination would cost approximately $42 per discounted case avoided.
INTERPRETATION: Routine varicella vaccination would likely substantially reduce the overall costs of managing chickenpox but would result in an increase in health care expenditures. These findings are consistent with evaluations in other countries.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12182379     DOI: 10.1097/00006454-200206000-00012

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

Review 1.  Economic evaluation of Varicella vaccination: results of a systematic review.

Authors:  Brigid Unim; Rosella Saulle; Sara Boccalini; Cristina Taddei; Vega Ceccherini; Antonio Boccia; Paolo Bonanni; Giuseppe La Torre
Journal:  Hum Vaccin Immunother       Date:  2013-07-03       Impact factor: 3.452

Review 2.  Economic evaluations of varicella vaccination programmes: a review of the literature.

Authors:  Nancy Thiry; Philippe Beutels; Pierre Van Damme; Eddy Van Doorslaer
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Varicella vaccination in Italy : an economic evaluation of different scenarios.

Authors:  Laurent Coudeville; Alain Brunot; Carlo Giaquinto; Carlo Lucioni; Benoit Dervaux
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Epidemiological characteristics of varicella from 2000 to 2008 and the impact of nationwide immunization in Taiwan.

Authors:  Luan-Yin Chang; Li-Min Huang; I-Shou Chang; Fang-Yu Tsai
Journal:  BMC Infect Dis       Date:  2011-12-16       Impact factor: 3.090

Review 5.  Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.

Authors:  Oliver Damm; Bernhard Ultsch; Johannes Horn; Rafael T Mikolajczyk; Wolfgang Greiner; Ole Wichmann
Journal:  BMC Public Health       Date:  2015-06-05       Impact factor: 3.295

Review 6.  Economic evaluations of vaccines in Canada: a scoping review.

Authors:  Ellen R S Rafferty; Heather L Gagnon; Marwa Farag; Cheryl L Waldner
Journal:  Cost Eff Resour Alloc       Date:  2017-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.